Long-Acting InjectableS
ADAP Advocacy strongly supports long-acting injectables (LAIs) as a promising new treatment option for people living with HIV/AIDS and a helpful HIV prevention tool for Pre-Exposure Prophylaxis (PrEP). LAIs can be administered once every few weeks or months, which can improve adherence, achieve viral suppression for PLWHA, and thus reduce the risk of HIV transmission.
Quick links
Take Action • Blogs • Inforgraphics • Op Eds • Policy Papers • Public Comments • Resources
LAIs include more than just antiretroviral therapies, such as Cabenuva or Sunlenca, which are used to treat HIV. They also include treatments such as Apretude, an injectable used as PrEP, Egrifta used to reduce visceral abdominal fat because of lipodystrophy, Serostim for wasting, and Trogarzo which is intravenous salvage therapy for those with multi-drug-resistant HIV infections. These therapies are proven effective, and their cost-benefit may be underappreciated, especially given the public health benefits of reduced new transmissions. There are also broader implications for LAIs and corresponding patient perspectives outside of the HIV space.
Obstacles and operational barriers to timely access to new agents, especially injectables, have increased. These products are vital to the well-being of people living with HIV/AIDS, as well as the prevention of new HIV diagnoses. The barriers that commonly arise hinder equitable access for PLWHA who rely on ADAP-funded services and other insurance products to obtain them on a regular basis. These same barriers often exist for PrEP. LAIs are powerful tools in the fight against HIV, and those utilizing AIDS Drug Assistance Programs (ADAP) deserve the same equity of care and access as those who are fully insured with more robust financial means. Whether it be geographical logistical challenges, treatment education deficiencies, supply chain issues, or even provider bias, ADAP recipients have many injection therapy barriers to overcome.
Click here to share your thoughts about long-acting injectables on our Discussion Board.
Long-Acting Injectable Agents Continue to Reshape the HIV Care Continuum
(August 21, 2025)
Long-acting injectable (LAI) agents remain at the forefront of medical innovation, especially regarding HIV treatment and prevention. LAIs are significant because they increase access options for people living with HIV/AIDS (PLWHA) for treatment, opening pathways for sustained viral suppression.
Blogs
State Payors Make Advancements in Coverage of HIV Long-Acting Injectable Treatments
(June 26, 2025)
As of June 2025, 47 state AIDS Drug Assistance Programs (ADAPs) and all state Medicaid programs offer coverage for Cabenuva (cabotegravir; rilpivirine), a long-acting injectable (LAI) for the treatment of HIV/AIDS.
View our blogs archive.
BACK TO TOPHIV LONG-ACTING INJECTABLES: Patient Access Considerations for Injectable HIV Therapies & Injectable HIV Pre-Exposure Prophylaxis
(June 2024)
In pursuing this project, ADAP Advocacy sought to understand patient perspectives on long-acting injectables (LAIs). This occurred through three methods – a quantitative survey, a qualitative focus group, and an examination of data – across two populations – those who are HIV-positive (the use of LAIs for treatment) and those who are HIV-negative (the use of LAIs for prevention).
Policy Papers
HIV LONG-ACTING AGENTS: Policy Considerations for Injectable Therapies under the Ryan White HIV/AIDS Program & State AIDS Drug Assistance Programs
(November 13, 2023)
This document outlines key topics for local community advocates and presents them in easy-to-digest concepts and context. At the end of the paper, you will find a robust list of hyperlinks to resources (digital/online), providing detailed information on each of these topics.
View our policy papers archive.
BACK TO TOPResources
Guidelines
Reports
The Policy Recommendations to Support Equitable Access to Long-Acting Injectables report offers policy advice to overcome barriers to care for uninsured individuals.
Resource Centers
The AAHIVM Long-Acting Agents Resource Center offers info on product availability, payment, and prescribing guidelines. It links visitors with clinicians using long-acting agents and provides a peer network for questions and sharing best practices.